NCT06971523View on ClinicalTrials.gov

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

December 25, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Solid TumorLymphoma
Interventions
DRUG

CTS3497

CTS3497: Orally via capsules

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

CytosinLab Therapeutics Co., Ltd.

INDUSTRY

NCT06971523 - A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | Biotech Hunter | Biotech Hunter